Voyager Therapeutics
Clinical trials sponsored by Voyager Therapeutics, explained in plain language.
Voyager Therapeutics
VYGR
NASDAQ
Gene therapy company developing treatments for neurological diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New Alzheimer's drug VY7523 enters human safety trials Results expected May 2027 (estimated)